ReviewInternational journal of ophthalmology2025
Photobiomodulation in ocular therapy: current status and future perspectives.
Review in International journal of ophthalmology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Therapeutic efficacy and safety of a multi-wavelength LED irradiation device in a rat model of meibomian gland dysfunction.Lasers in medical science · 2026Article
- Role of light in eye growth and light as a therapy for myopia control.Frontiers in ophthalmology · 2026Review
- Effectiveness of photobiomodulation therapy for ophthalmic diseases: protocol for a systematic review and meta-analysis of disease-specific and shared physiological outcomes.Systematic reviews · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Photobiomodulation has been known to have potential medicinal effects for ages. It involves the use of specific wavelengths to target specific regions in the cell. Different health conditions have been reported to be treated with exposure to light such as cardiovascular conditions, inflammatory diseases, infectious diseases, and most importantly ocular diseases. This review specifically targets the treatment of retinal diseases including age-related macular degeneration, diabetic macular edema, myopia and acute retinal light injury with photobiomodulation. Red light is used in this therapy since this wavelength has lower frequency and hence minimal chance of causing any damage. Red light has the potential to penetrate cellular structures such as mitochondria and facilitate cellular processes. For ocular diseases, the target wavelength ranges between 630 to 800 nm. In most of the cases the primary target for red light is the cytochrome C oxidase enzyme in mitochondria, which alters the gene expression and promotes cellular energy production. Clinical evidence shows improvement of visual activity and reduction in thickness of retina post treatment. Future prospects of photobiomodulation involve target-specific treatment, combinational therapy to treat complex retinal diseases including gene therapy, and longitudinal studies to predict long-term efficacy and the chance of any recurrence in the patients. Hence the future of photobiomodulation holds significant potential in medicine especially in ocular diseases characterized by progress in research, technology, and clinical trials.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.